This reports provides a data-driven overview of the current and future competitive landscape in soft tissue sarcoma therapeutics.
- In 2024, more than 300,000 diagnosed prevalent cases of STS are anticipated in the 16 countries covered in GlobalData's epidemiology forecast for STS.
- Currently, the market space for STS holds many innovator drugs. Prominent companies such as Roche, BMS, Novartis, and Boehringer Ingelheim are the key players for STS.
- R&D activities for STS are strong with 361 molecules in the pipeline, out of which the late-stage pipeline holds 10 drugs.
- The US is emerging as the key country for conducting STS trials.
- Partnerships dominated the deal landscape in North America, Europe and Asia-Pacific.
Scope
GlobalData's soft tissue sarcoma: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the soft tissue sarcoma market.
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global soft tissue sarcoma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.